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chizophrenia and bipolar affective disorder
(bipolar disorder, manic depression) are major psychi-
atric disorders. They profoundly affect thought, percep-
tion, emotion, and behavior, and their symptoms cause
significant social and/or occupational dysfunction. The
World Health Organization ranks both disorders among
the top 10 leading causes of the global burden of disease
for the 15-to-44 age group.
Schizophrenia and bipolar disorder are illnesses with a
largely unknown pathophysiology and etiology. However,
genetic epidemiology has demonstrated that modern psy-
chiatric diagnostic criteria define disorders that are highly
heritable. Estimates of heritability range between 70%
and 90% for schizophrenia
1 and 60% and 80% for bipo-
lar disorder.
2 It is generally accepted that the inheritance
of psychiatric disorders is complex. Multiple genetic and
environmental factors contribute to the development of
a disorder
3-9 and it is possible that gene-gene interactions
also occur.
10,11
Extensive efforts have been made over the past 20 years
to identify the susceptibility genes for psychiatric disor-
ders on a molecular genetic level, although this has
proven to be a far more difficult undertaking than was
first anticipated. Until recently, the linkage approach and
microscopic cytogenetic studies were the only available
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Schizophrenia and bipolar disorder have a largely
unknown pathophysiology and etiology, but they are
highly heritable. Although linkage and association stud-
ies have identified a series of chromosomal regions likely
to contain susceptibility genes, progress in identifying
causative genes has been largely disappointing. However,
rapid technological advances are beginning to lead to
new insights. Systematic genome-wide association and fol-
low-up studies have reported genome-wide significant
association findings of common variants for schizophre-
nia and bipolar disorder. The risk conferred by individual
variants is small, and some variants confer a risk for both
disorders. In addition, recent studies have identified rare,
large structural variants (copy number variants) that con-
fer a greater risk for schizophrenia. This review summa-
rizes recent developments in genetic research into schiz-
ophrenia and bipolar disorder, and discusses possible
future directions in this field.   
© 2010, LLS SAS Dialogues Clin Neurosci. 2010;12:85-93.
85 Copyright © 2010 LLS SAS.  All rights reserved www.dialogues-cns.org
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 85methods of systematically searching the genome. A dis-
advantage of these two methods is their low level of res-
olution. Linkage studies have identified a series of chro-
mosomal regions that are likely to contain susceptibility
genes, and highly promising association findings have
been obtained for several genes in these regions (eg,
neuregulin 1 [NRG1], G72/G30 locus, dystrobrevin-bind-
ing protein 1 [DTNBP1]).
12-14 However, it has not yet
been possible to identify any genetic variant that confers
a direct functional effect and which is consistently asso-
ciated with disease across populations. Cytogenetic stud-
ies have also generated some highly promising candidate
genes such as the disrupted-in-schizophrenia-1 gene
(DISC1).
15 Subsequent studies have reported highly
interesting findings regarding the function of these genes
and their associated pathways.
16
Recently, however, important advances have been made
as a result of rapid developments in technologies that
are able to decipher the variability of the human
genome at high resolution, and which allow systematic
investigation of the impact of such variability in large
samples. This article summarizes these developments in
genetic research into schizophrenia and bipolar disorder,
and discusses possible future directions in this field.
Genome-wide association studies
The introduction of the genome-wide association study
(GWAS) is the result of enormous technological
advances. GWASs involve the use of arrays that simul-
taneously genotype several hundred thousand single
nucleotide polymorphisms (SNPs) per individual. This
enables a hypothesis–free search of every gene and most
intergenic regions of the genome in samples of unrelated
patients and controls. In this respect GWASs resemble
genome-wide linkage studies (genome scans), but they
have several major advantages: (i) they are not depen-
dent on the recruitment of families; (ii) they have better
resolution since (in contrast to linkage) they detect link-
age disequilibrium with susceptibility variants, which
usually extends over smaller genomic regions (in the
range of a few ten thousand base pairs); and (iii) they
have greater power to detect small genetic effects. In
contrast to linkage studies, however, they are restricted
to the investigation of common variants, since SNPs with
low minor allele frequencies are poorly represented on
currently available arrays. A serious difficulty in evalu-
ating the results of GWASs is the issue of multiple test-
ing. A large number of SNPs may be tested within the
same study for their association with a disease, and this
generates many nominally significant findings that are
actually false positives. It is therefore necessary to cor-
rect for multiple testing to achieve the level of genome-
wide significance. This level is dependent upon the num-
ber of SNPs analyzed, and the threshold for currently
available GWA chips is approximately 5 x 10
-8 (660 000
to 1 000 000 SNPs).
17-19 This correction method is very
conservative since the association findings of each SNP
are considered to be independent, and the haplotype
structure of the genome is not taken into account.
Conservative correction for multiple testing reduces the
risk of false-positive findings, but hampers the detection
of true association signals that represent small effects on
disease risk.
Following the publication of the first GWAS in age-
related macular degeneration,
20 successful GWASs have
been conducted for a variety of common, complex dis-
eases including type 2 diabetes, myocardial infarction,
breast cancer, and Crohn’s disease (for details of all pub-
lished studies see http://www.genome.gov/gwastudies/).
Schizophrenia
The first GWASs for schizophrenia have recently been
published.
21-30 Three of these studies used pooled DNA
samples.
21,26,27 The best supported variants in these three
studies failed to achieve genome-wide significance 
21,26,27
(Table I). This is a cost-effective method of performing
GWASs and has proved to be effective in identifying dis-
ease genes (eg, refs 31,32). However, due to errors in
DNA quantification, this method is less sensitive than
individual genotyping and has less power. Furthermore,
the evaluation of data is limited to the study of (esti-
mated) allele frequencies at the level of individual SNPs.
This method does not detect the effect of haplotypes,
interactions between SNPs, or the effects of genotypes
that do not show differences in allele frequencies. The
first individual-genotyping-based GWAS of schizophre-
nia involved a very small sample of 178 cases and 144
controls.
29The best hit was for a variant near the colony-
stimulating factor-2 receptor alpha (CSF2RA) gene, but
this did not achieve genome-wide significance.
29The sec-
ond GWAS of this type included 738 patients and 733
controls. Although a few signals coincided with genomic
regions that had been implicated in previous linkage
studies of schizophrenia, this study found no genome-
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Study N° SNPs  Supported  Supported  Genomic  P value N° samples  P value N° samples, 
analyzed gene variant region discovery discovery combined replication/ 
meta-analysis
Mah et al  ~ 25 000 plexin A2 (PLXNA2) rs752016 1q32.2 0.006 320 cases 0.035 200 cases (EA)
(2006) 325 controls 230 controls (EA)
Lencz et al  ~ 500 000 colony stimulating rs4129148 Xp22.33 3.7 x 10
-7 178 cases ND ND
(2007) factor receptor 2 Yp22.32 144 controls
alpha (CSF2RA)
Sullivan et al  ~ 500 000  nearest gene:  rs4846033 1p36.22 4.4 x 10
-6 738 cases ND ND
(2008) angiotensin II receptor- 733 controls
associated protein
(AGTRAP)
O´Donovan et al ~ 500 000 zinc finger protein rs1344706 2q32.1 1.8 x 10
-6 479 cases 1.6 x 10
-7 7308 cases
(2008) 804A (ZNF804A) 2937 controls 12834 controls
Shifman et al  ~ 500 000 reelin (RELN) rs7341475 7q22.1 2.9 x 10
-5 745 cases 8.8 x 10
-7 2274 cases
(2008) (in females) 2644 controls (in females) 4401 controls
Kirov et al  ~ 550 000 coiled coiled domain rs11064768 12q24.23 1.2 x 10
-6 574 trios  ND ND
(2009) containing 60 (CCDC60)
Need et al  ~ 550 000 ADAMTS like 3 rs2135551 15q25.2 1.3 x 10
-6 871 cases NR 1460 cases
(2009) (ADAMTSL3) 863 controls 12995 controls
Shi et al (2009) ~ 600 000 ArfGAP with GTPase rs13025591 2q37.2 4.6 x 10
-7 2681 cases ND
domain, ankyrin repeat (in EA) 2653 controls
and PH domain 1 (EA)
(AGAP1)
v-erb-a erythroblastic rs1851196 2q34 2.1 x 10
-6 1286 cases ND
leukemia viral oncogene (in AA) 973 controls
homolog 4 (avian) (AA)
(ERBB4)
major histocompatibility rs9272219 6p21.32 ND 6.9 x 10
-8 8008 cases (EA)
complex (MHC) rs9272535 6p21.32 ND 8.9 x 10
-8 19077 controls (EA)
cluster of histone rs13194053 6p22.1 1.4 x 10
-2 9.5 x 10
-9
protein genes (in EA)
The  ~ 1 000 000 myosin XVIIIB rs5761163 22q12.1 3.4 x 10
-7 3322 cases ND 8008 cases
International (MYO18B)  3587 controls  9.5 x 10
-9 19077 controls
Schizophrenia major histocompatibility rs13194053 6p22.1 ND
Consortium (2009) complex (MHC)
Stefansson et al ~ 300 000 major histocompatibility 5 variants 6p21.3 – 0.0027- 2663 cases 1.1 x 10
-9- 12945 cases
(2009) complex (MHC) 6p22.1 0.00023 13498 controls 1.4x 10
-12 34591 controls
neurogranin (NRGN) rs12807809 11q24.2 0.00045 2.4 x 10
-9
transcription factor 4 rs9960767 18q21.1 0.0011 4.1 x 10
-9
(TCF4)
Table I. Published genome-wide association studies (GWASs) for schizophrenia.
21-30,32 The number of variants investigated, the best associated sin-
gle-nucleotide polymorphism(s)–SNP(s)—found and the gene(s) containing the SNP(s), the corresponding P value(s), and the number of cases
and controls in the discovery and the replication/meta-analysis sample are all given. Genome-wide significant findings are highlighted in bold.
EA, European Ancestry Individuals; AA, African-American Individuals; ND, no data available; NR, no replication
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30 O’Donovan et al initially
performed a GWAS using a moderately sized patient
sample (n=479). They then performed a follow-up study
of 12 markers with a P value ≤10
-5 in a much larger sam-
ple to enhance the statistical power.
25 Strong evidence
for replication was obtained for 3 of these 12 markers (P
≤5 x 10
-4), although the best supported variant still failed
to achieve genome-wide significance (Table I). The high-
est-ranking SNP identified in this study is located in an
intron of the zinc finger protein 804A gene (ZNF804A),
a putative transcription factor which had never been
implicated previously in the risk for schizophrenia. The
case sample was then extended to include bipolar
patients. The P value for the total sample surpassed the
level of genome-wide significance (P=9 x 10
-9). The asso-
ciation between ZNF804A and schizophrenia has
recently been replicated by the International
Schizophrenia Consortium,
24 and ZNF804A is therefore
a promising susceptibility gene for schizophrenia. A
recent imaging genetics study of ZNF804A risk geno-
types has provided evidence in support of these genetic
findings. This study demonstrated that healthy carriers
of ZNF804A risk genotypes display pronounced gene-
dosage-dependent alterations in functional coupling
between the hippocampus and the dorsolateral pre-
frontal cortex (DLPFC) across the two hemispheres,
which mirrors findings in patients.
33
Three recent multicenter studies have provided impor-
tant insights. The initial findings of these three studies
failed to surpass the level of genome-wide significance.
However, a meta-analysis was then performed using the
best hits from the European data of these studies and
data from a replication study by Stefansson et al.
22 This
revealed a cluster of genome-wide significant SNPs in
the major histocompatibility (MHC) region of chromo-
some 6p22.1 that were in substantial linkage disequilib-
rium.
22-24 These results provide evidence that the
immunological system may play a role in the pathogen-
esis of schizophrenia. Furthermore, a variant upstream
of neurogranin (NRGN; P=2.4 x 10
-9) and a SNP in tran-
scription factor 4 (TCF4; P= 4.1 x 10
-9) achieved genome-
wide significance in Stefansson et al's study.
22These stud-
ies demonstrate that GWASs of large samples can
overcome limitations in power and detect common risk
variants for complex psychiatric disorders.
In the study by the International Schizophrenia
Consortium, it was demonstrated that possible risk vari-
ants may have been among the nominally significant
SNPs that failed to reach genome-wide significance.
Nominally significant SNPs were grouped into a “set of
score alleles” and analyzed in an independent case-con-
trol sample, and it was shown that they distinguished
cases from controls.
24This study also demonstrated that
this set of genes distinguished bipolar cases from con-
trols, thus providing further evidence for a genetic over-
lap between schizophrenia and bipolar disorder.
Although these SNPs explained only approximately 3%
of the variance in schizophrenia risk, this may be
regarded as a step towards molecular genetic evidence
for the polygenic inheritance of schizophrenia.
Bipolar disorder
Six GWASs have been published to date for bipolar dis-
order
34-39 (Table II) including the landmark study by the
Wellcome Trust Case Control Consortium (WTCCC)
which investigated seven common disorders.
36 These
studies were all based upon individual genotyping, with
the exception of the study by Baum et al
39 which
involved DNA pooling. Although there has been some
inconsistency across studies in terms of their most asso-
ciated genomic regions,
35-39 meta-analyses of some of
these studies have revealed common association signals.
A meta-analysis of the Baum et al
39 and the WTCCC
36
datasets found a consistent association between bipolar
disorder and variants in the genes junction adhesion mol-
ecule 3 (JAM3) (rs10791345, P=1 x 10
-6), and solute car-
rier family 39 (zinc transporter), member 3 (SLC39A3)
(rs4806874, P=5 x 10
-6).
40 A combined analysis of the
Sklar et al
35 and WTCCC
36 studies, which included a total
of 4387 patients and 6209 controls, identified the first
genome-wide significant association signal for bipolar
disorder for ankyrin 3, node of Ranvier (ANK3)
(rs10994336, P=9.1 x 10
-9).
34 The second most strongly
associated region was marked rs1006737 in calcium
channel, voltage-dependent, L type, alpha 1C subunit
CACNA1C (P=7 x 10
-8). Further independent support
for ANK3 rs10994336 has recently been obtained by
Schulze et al
41 in samples from Germany and the United
States (US); this study also found evidence for allelic
heterogeneity at the ANK3 locus.
Although GWASs of bipolar disorder have identified a
number of potentially relevant genetic variants, the
widely acknowledged formal threshold for genome-wide
significance of P=5 x 10
-8 has only been surpassed so far
for variation in ANK3.
Clinical research
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datasets, and higher statistical power are expected to
identify additional specific risk factors for bipolar disor-
der and schizophrenia. 
Copy number variations
Small chromosomal aberrations (microdeletions and
microduplications, collectively known as copy number
variations, CNV) may confer a risk for schizophrenia, as
illustrated by the 22q11.2 deletion syndrome (22q11.2DS).
This is a common microdeletion syndrome with congeni-
tal and late-onset features. Patients have a high risk for
neuropsychiatric diseases including psychotic disorders
and major depression.
42-44 It has not been possible to cor-
relate the extent of the deletion with the occurrence of
schizophrenia in these patients, and there is experimental
evidence that increased susceptibility may require the
altered expression of several genes within the 22q11.2
region.
45,46This may explain why no replicable results have
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Study N° SNPs  Supported  Supported  Genomic  P value N° samples,  P value N° samples, 
analyzed gene variant region discovery discovery combined replication/ 
meta-analysis
Baum et al  ~ 550 000 diacylglycerol kinase rs1012053 13q14.11 0.0002 461 cases 1.5 x 10
-8 772 cases
(2007) eta (DGKH) 563 controls 876 controls
Welcome Trust  ~ 500 000 partner and localizer rs42059 7q21.3 6.3 x 10
-8 1868 cases ND ND
Case Control  of BRCA2 (PALB2) 2938 controls
Consortium 
(WTCCC; 2007)
Sklar et al  ~ 400 000 tetraspanin-8 (TSPAN8) rs1705236 12q21.1 6.1x 10-
7 1461 cases NR
(2008) myosin5B (MYO5B) rs4939921 18q21.1 1.7 x 10
-7 2008 controls NR
voltage-dependent 3329 cases
calcium channel, L-type, rs1006737 12p13.33 8.8 x 10
-4 3.1 x 10
-6 4946 controls
alpha 1C subunit
(CACNA1C)
Ferreira et al  ~ 1 800 000 ankyrin G (ANK3) rs10994336 10q21.2 0.0002 1098 cases 9.1 x 10
-9 4387 cases
(2008) (imputed)  rs1938526 10q21.2 0.0002 1267 controls 1.3 x 10
-8 6209 controls
~ 300 000 voltage-dependent rs1006737 7.0 x 10
-8
(genotyped) calcium channel, L-type, 12p13.33 0.0108
alpha 1C subunit
(CACNA1C)
Scott et al ~ 550 000 inter-alpha (globulin) rs1042779 3p21.1 2076 cases 1.8 x 10
-7 3683 cases
(2009) inhibitor H1 (ITIH1) 1676 controls 14507 controls
multiple C2 domains, rs17418283 5q15 ND
transmembrane 1 1.3 x 10
-7
(MCTP1)
nuclear factor 1 A-type rs472913 1p32.1 2.0 x 10
-7
(NF1A)
Smith et al  ~ 700 000 nck-associated protein 5 rs10193871 2q21.2 9.8 x 10
-6 1001 cases ND ND
(2009) (NAP5) 1033 controls
(EA)
dpy-19-like 3 (DPY19L3) rs2111504 19q13.11 1.5 x 10
-6 345 cases
670 controls
(AA)
Table II. Published genome-wide association studies (GWASs) for bipolar disorder.
34-39 The number of variants investigated, the best associated single-
nucleotide polymorphism(s)–SNP(s)—found and the gene(s) containing that SNP(s), the corresponding P value(s), and the number of cases
and controls in the discovery and the replication/meta-analysis sample are all given. Genome-wide significant findings are highlighted in bold.
EA, European Ancestry Individuals; AA, African-American Individuals; ND, no data available; NR, no replication
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genes within the deletion region as susceptibility genes for
schizophrenia.
47
Schizophrenia
The application of new technologies such as compara-
tive genomic hybridization (CGH) and SNP arrays in
GWASs has enabled the identification of small chromo-
somal aberrations on a genome-wide scale. Initial stud-
ies reported an increased rate of aberrations in schizo-
phrenia
48,49 and subsequent studies have implicated
specific chromosomal regions.
28,50-54 Implicated aberra-
tions include microdeletions in chromosomal regions
1q21.1, 2p16.3, 15q11.2, and 15q13.3, as well as microdu-
plications in chromosomal regions 15q13.1 and 16p11.2.
Although all of these variants are observed more fre-
quently in patients than in controls (with odds ratios of
>10 for some variants), the frequency of each individual
variant in schizophrenia patients is low (<1%). Further
studies are required to determine the penetrance and
mutation rate of these aberrations, as well as their phe-
notypic spectrum. Research has shown that some vari-
ants also occur more frequently in patients with other
central nervous system phenotypes such as autism, men-
tal disability, and epilepsy.
55-58 The mechanisms that
underlie the phenotypic outcome however, remain
unknown. The fact that de novo mutations are found in
a proportion of patients with CNVs supports the hypoth-
esis that the negative effect on reproductive fitness
observed in schizophrenia patients may be at least partly
offset by the occurrence of new mutations.
Bipolar disorder
There have been few CNV studies of bipolar disorder.
59-61
Lachman et al investigated a mixed cohort of Caucasian
patients (n=227) and controls (n=276) from the Czech
Republic and the United States, and found that CNVs
involving the gene glycogen synthase kinase 3 beta
(GSK3beta) were significantly increased in patients com-
pared with controls.
59 Using a European American sample
of 1001 BD patients and 1034 controls, Zhang et al inves-
tigated singleton microdeletions (ie, those occurring only
once in the total dataset of patients and controls) of more
than 100 kb and found that they were overrepresented in
patients.
60 The effect was strongest in a subgroup of
patients with an early onset of mania (<18 years of age). A
recent study of a three-generation Older Amish pedigree
with segregating affective disorder
61 identified a set of 4
CNVs on chromosomes 6q27, 9q21, 12p13, and 15q11 that
were enriched in affected family members and which
altered the expression of neuronal genes.
No CNV with a genetic effect comparable to those iden-
tified for neuropsychiatric disorders such as schizophre-
nia or autism has yet been identified for bipolar disor-
der. In view of the limited number of studies performed,
it is not possible to evaluate the influence of CNVs on
disease development. 
Outlook
The first GWASs of schizophrenia and bipolar disorder
have recently been published, and many more are in
progress. Large international collaborations have been
initiated to combine GWAS data sets in order to increase
statistical power, the largest being the Psychiatric GWAS
Consortium, which is expected to publish its first results
in 2010 (The Psychiatric GWAS Consortium Steering
Committee 2009). Currently available research findings
suggest that the variants identified through GWASs con-
fer only small individual risks. The major limitation of
GWASs is that they are only able to investigate common
variants. If a large fraction of the genetic contribution is
conferred by rare variants, other approaches will be nec-
essary to identify them. A successful first step in this
direction has been the identification of associations
between rare CNVs and psychiatric diseases, in particu-
lar schizophrenia. However, due to methodological con-
straints, this approach remains restricted to the investi-
gation of aberrations of at least several thousand base
pairs. Continuing technological developments will pro-
vide future studies with increasing resolution, and the
availability of low-cost whole genome sequencing tech-
nology will ultimately make it possible to obtain the com-
plete genomic sequences of large patient samples for
comparison with controls. In principle, this will allow the
systematic identification of rare variants that are associ-
ated with disease risk, although the existence of a myriad
of rare variants in the human genome will render this a
complex task. It is hoped that some rare variants confer
a larger disease risk, as this will facilitate the detection of
association in large case-control samples. Rare variants
with small disease risk may be extremely difficult to
detect, since prohibitively large sample sizes may be
required to demonstrate any significant association. 
Clinical research
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all common and rare risk variants a substantial fraction
of the familial clustering will remain unexplained. This
“missing heritability” in complex diseases is the subject
of intense debate and several potential explanations
have been proposed, including epistasis and epigenetic
mechanisms.
62-64 It will be necessary to apply specific
research strategies to further investigate this issue,
although these may require prohibitively large sample
sizes or tissue samples that are difficult to access in
human subjects.
It is not yet clear whether any of the association findings
identified by GWASs represent causal variants.
Systematic resequencing of the associated genomic
regions will provide a comprehensive overview of such
variants. In cases where association findings are due to
linkage disequilibrium, it is possible that the causal vari-
ants have a stronger genetic effect than has been previ-
ously suspected. It is also theoretically possible that a
given association finding is not attributable to a common
causal variant. A simulation study has shown that the
“synthetic” effect of multiple rare variants may be
responsible for signals detected for common variants. It
has also been shown that the location of these variants
may be relatively far (up to 2 megabases) from the site
identified in GWASs.
65 If this were the case for an asso-
ciated locus, resequencing over large genomic distances
in large samples would be required to identify the true
causative variants. Ultimately, it is necessary to identify
a direct functional effect for each potential causal vari-
ant, such as an effect on the function or expression of a
gene.
GWASs performed to date have indicated that certain
genes contribute to a susceptibility to both schizophre-
nia and bipolar disorder. It is clear that some of these
genes convey a rather nonspecific susceptibility that
overlaps diagnostic boundaries, and it is highly probable
that this also overlaps with other psychiatric disorders.
Other genes, however, convey specific effects. Future
studies of the phenotypic dimensions that are most
strongly associated with a specific gene will include
analysis of clinical symptoms and endophenotypes. The
latter may be particularly suited to guiding researchers
in the selection of the most promising phenotypes for
animal studies.
66
The identification of disease-associated genes is likely to
increase our knowledge of the underlying pathophysiol-
ogy of psychiatric disorders in an as-yet unforeseen man-
ner. The identification of biological pathways has the
potential to revolutionize diagnostics and treatment.  ❏
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Nuevos hallazgos en la genética de las 
principales psicosis
La esquizofrenia y el trastorno bipolar tienen una
etiología y una fisiopatología en gran medida
desconocidas, pero son altamente heredables.
Aunque los estudios de ligamiento y de asociación
han identificado una serie de regiones cromosó-
micas que contienen probablemente genes sus-
ceptibles, el progreso en la identificación de
genes causales ha sido muy decepcionante. Sin
embargo, los rápidos avances tecnológicos están
dando origen a nuevos conocimientos. Los estu-
dios sistemáticos de asociación del genoma com-
pleto y de seguimiento han informado acerca de
hallazgos de asociación significativa del genoma
completo y variantes comunes para la esquizo-
frenia y el trastorno bipolar. El riesgo que deter-
minan las variantes individuales es pequeño y
algunas de ellas confieren un riesgo para ambos
trastornos. Además, estudios recientes han iden-
tificado variantes estructurales largas y raras
(variantes de número de copias) que otorgan un
mayor riego para la esquizofrenia. Esta revisión
resume los desarrollos recientes en la investiga-
ción genética de la esquizofrenia y del trastorno
bipolar y discute las posibles direcciones futuras
en este campo. 
Nouvelles découvertes en génétique des
principales psychoses
La physiopathologie et l’étiologie de la schizo-
phrénie et des troubles bipolaires restent large-
ment méconnues mais fortement héréditaires.
Des études de liaison et d’association ont identi-
fié des séries de régions chromosomiques conte-
nant probablement des gènes de susceptibilité,
mais l’identification des gènes de causalité est
extrêmement décevante. Des avancées technolo-
giques rapides commencent cependant à voir le
jour. Des études systématiques d’association sur le
génome entier et de suivi ont découvert une asso-
ciation significative au niveau du génome entier
de variants communs pour la schizophrénie et les
troubles bipolaires. Le risque inhérent aux
variants individuels est faible, et certains variants
comportent un risque pour les deux pathologies.
De plus, des études récentes ont identifié des
variants structurels importants et rares (CNV =
copy number variants, variants du nombre de
copies) liés à un risque plus élevé de schizophré-
nie. Cet article résume les avancées récentes de la
recherche génétique concernant la schizophrénie
et les troubles bipolaires et analyse les perspec-
tives possibles dans ce domaine.
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